This study is in progress, not accepting new patients
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Summary
- Eligibility
- for people ages 18-120 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Antoni Ribas, MD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Antoni Ribas, MD
Antoni Ribas, M.D., Ph.D., holds the Rosalyn R. Shostak Heyman and Hannah Kully Shostak Endowed Chair.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Clinical Trials Information Plain Language Summary Sign up for this study
- ID
- NCT04305041
- Phase
- Phase 1/2 Skin Cancer/Melanoma Research Study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated